<p>
<strong><u>Release Date</u></strong><br/>
October 23, 2014<br/><br/>
<strong><u>Expiration Date</u></strong><br/>
October 23, 2015<br/><br/>

<strong><u>Faculty</u></strong><br/>
Susan O'Brien, MD<br/>
The University of Texas<br/>
MD Anderson Cancer Center<br/>
Houston, Texas, United States<br/><br/>

<strong><u>Learning Objectives</u></strong><br/>
After successful completion of  this educational activity, participants should be able to:
<ul class="bullets">
  <li>Employ best practices regarding response  assessment and monitoring of patients with chronic myeloid leukemia (CML) and adjust treatment plans at  appropriate time points based on current recommendations</li>
  <li>Incorporate findings from cytogenetic and  molecular testing when treating patients with CML, including time-based  response milestones</li>
  <li>Evaluate barriers to treatment in the management  of CML and employ effective strategies to overcome them to improve patients  care</li>
</ul>
<br/>

<strong><u>Provider</u></strong><br/>
This activity is provided by prIME Oncology.<br/><br/>

<strong><u>Support</u></strong><br/>
<p>This educational activity is supported by a grant from Bristol-Myers Squibb.<br/><br/>

<strong><u>Target Audience</u></strong><br/>
This educational activity is specifically designed  for hematologists, oncologists, and other healthcare professionals interested  and/or involved in the treatment of patients with  CML.<br/><br/>

<strong><u>Continuing Medical Education</u></strong><br/>
prIME Oncology is accredited by the  Accreditation Council for Continuing Medical Education (ACCME<sup>&reg;</sup>) to  provide continuing medical education for physicians.<br/><br/>
prIME Oncology designates  this live activity for a maximum of <em>0.5 AMA PRA Category 1  Credits<sup>&trade;</sup>.&nbsp;</em>Physicians  should claim only the credit commensurate with the extent of their  participation in the activity.<br/><br/>


<strong><u>Method of Participation</u></strong><br/>
There are no fees for participating in and  receiving CME credit for this activity. In order to receive credit,  participants must successfully complete the online posttest and activity  evaluation. Your participation in this CME activity will be recorded in prIME  Oncology's database. However, upon request, your CME credit certificate will be  emailed to you.<br><br>

Technical requirements may be found under  the&nbsp;<a href="http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx">Terms  of Use</a>.<br><br>

Links to the posttest are available on the  video player pages.<br/><br/>

In order to claim credit for this activity, a  score of 75% or higher is required.<br/><br/>

<strong><u>Disclosure of Relevant Financial Relationships</u></strong><br/>
prIME Oncology assesses relevant financial  relationships with its instructors, planners, managers, and other individuals  who are in a position to control the content of CME activities. Any potential conflicts  of interest that are identified are thoroughly vetted by prIME Oncology for  fairness, balance, and scientific objectivity of data, as well as patient care  recommendations. prIME Oncology is committed to providing its learners with  high-quality CME activities and related materials that promote improvements or  quality in healthcare and not a specific proprietary business interest of a  commercial entity.<br/><br/>

<strong>Faculty Disclosures</strong><br/>
The faculty reported the following financial  relationships or relationships to products or devices they or their  spouses/life partners have with commercial interest related to the content of  this activity:<br/><br/>

  Dr O&rsquo;Brien disclosed  that she has received consulting fees from Amgen; Celgene; Emergent; Genentech;  Gilead Sciences; GlaxoSmithKline; Infinity; Pharmacyclics; Talon; and  Teva/Cephalon. She has also received research funding from Emergent; Genentech;  Gilead Sciences; Infinity; MorphoSys; Pharmacyclics; and Talon. In addition, Dr  O&rsquo;Brien has received fees for participation in advisory boards from CLL Global  Research Foundation. She has agreed to disclose any unlabeled/unapproved uses  of drugs or products referenced in her presentation.<br/><br/>
  
The employees of prIME Oncology have  disclosed:</p>
<ul type="disc">
  <li>Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial       relationships</li>
  <li>Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships</li>
</ul>

<p><br/>
<strong><u>Disclosure Regarding Unlabeled Use</u></strong><br/>
This  activity may contain discussion of published and/or investigational uses of  agents that are notindicated by the US Food and Drug Administration or European  Medicines Agency. Please refer to the official prescribing information for each  product discussed for discussions of approved indications, contraindications,  and warnings.<br/><br/>

<strong><u>Disclaimer</u></strong><br/>
Participants have an implied responsibility to  use the newly acquired information to enhance patient outcomes and their own  professional development. The information presented in this activity is not  meant to serve as a guideline for patient management. Any procedures,  medications, or other courses of diagnosis or treatment discussed or suggested  in this activity should not be used by clinicians without evaluation of their  patients' conditions and possible contraindications or dangers in use, review  of any applicable manufacturer's product information, and comparison with  recommendations of other authorities.<br/>
</p>